ZYUS Life Sciences says 3 of 7 evaluable patients met pain threshold
The uncontrolled Canadian trial enrolled 11 patients; seven were evaluable for pain, and validated data analysis remains underway.
Theo Marchetti
At three Canadian trial sites, Phase 2a cancer-pain results released Oct. 1 showed that three of seven evaluable patients reached a predefined 30 per cent reduction in average pain. ZYUS Life Sciences Corporation CVEZYUS said its Trichomylin capsules were given to 11 patients in UTOPIA-1 alongside standard pain treatment, including long-acting opioids.
The Oct. 1 release says ZYUS plans to incorporate opioid reduction for both long-acting and breakthrough opioids as a co-primary endpoint alongside pain efficacy in future trials. The trial record last updated Sept. 1 lists one unmasked treatment arm, so these results cannot establish how Trichomylin performs against standard treatment alone.
The CVEZYUS quote showed ZYUS at C$0.60 at the Sept. 30, 4 p.m. EDT close on the TSX Venture Exchange, before the Oct. 1 announcement. That close provides a pre-release reference; it does not measure a trading reaction to the topline.
The company says final interpretation awaits validated analysis of its programmed dataset. It plans to present the topline figures at the Montreal International Palliative Care Congress in October 2026, its next stated public milestone.
Pain Signal Comes From Seven Patients
The September 2026 company analysis says 10 of 11 treated patients reached a stable individualized dose, the trial's titration objective. All 11 continued standard pain management, including long-acting opioids, while taking the capsules for as long as 23 days. Pain-response calculations used only the seven patients who adhered to the treatment and assessment plan.
Among those seven, three met the predefined 30 per cent average-pain threshold. Two met the threshold on pain severity and four on pain interference. The company's September report puts the 95 per cent confidence interval around the average-pain responder share at 9.9 to 81.6 per cent, showing how uncertain the estimate remains.
No treatment-related serious adverse events were recorded among 11 participants. The September report also lists one severe treatment-related fatigue event during the discontinuation phase.
Opioid Use Remains Exploratory
The ClinicalTrials.gov record updated Sept. 1 identifies Trichomylin as a fixed-dose combination of THC, CBD and CBC, with five milligrams of each per capsule. Participants could adjust the number of capsules during titration, while the cannabinoid ratio remained fixed.
Read more: DEA judge stays marijuana rescheduling hearing over GAO report motion
All seven evaluable patients had rescue opioids prescribed for breakthrough pain, and two did not use them while taking Trichomylin, ZYUS said on Oct. 1. Because there was no comparison arm, those observations do not show that the capsules reduced opioid use. The company proposes testing reduced use of both rescue and long-acting opioids in future trials.
"The internal data and observations support conditional advancement into controlled trials but are treated as preliminary until the final validated analyses are completed with programmed data," ZYUS said in its September 2026 report.
The next dated public checkpoint is the Montreal International Palliative Care Congress in October 2026, where ZYUS says it will present the topline.
